Acute Tubular Necrosis
Acute cannular mortification is urinary organ injury caused by harm to the urinary organ tube
cells (kidney
cells that absorb fluid and minerals from excretory product because it forms). Common causes square measure low blood flow to the kidneys (such as caused by low blood pressure), medication that harm the kidneys, and severe bodywide infections. A number of issues will cause acute cannular mortification. However, the foremost frequent causes square measure conditions that cut back atomic number 8 to the kidneys. These embody polygenic disorder, a stroke, or a attack. Chemicals may harm the tubules. Acute cannular mortification (ATN) follows a well-defined three-part sequence of initiation, maintenance, and recovery (see below). The tube cell harm associate degreed necrobiosis that characterize ATN sometimes result from an acute ischaemic or ototoxic event. Your doctor might impose medication to decrease the fluid and
waste buildup in your kidneys. you'll even be told to limit your diet to cut back your intake of Na and K. Prognosis. Outcome depends on correction of the disorder that caused acute cannular mortification. If that disorder responds speedily to treatment, urinary organ operate sometimes returns to traditional in one to three weeks. Prognosis is sometimes higher if people's excretory product volume exceeds four hundred metric capacity unit (about thirteen.5 ounces) each twenty four hours.
High Impact List of Articles
-
The effect of a combination treatment of biomagnetic therapy and a low glycaemic influenced diet on nonfasting blood glucose levels in type 2 diabetic rats
Williams M*, Asemota HN+, Williams E, McGrowder D, Nwokocha C , Voutchkov M and Francis R
Research Article: Diabetes Management
-
The effect of a combination treatment of biomagnetic therapy and a low glycaemic influenced diet on nonfasting blood glucose levels in type 2 diabetic rats
Williams M*, Asemota HN+, Williams E, McGrowder D, Nwokocha C , Voutchkov M and Francis R
Research Article: Diabetes Management
-
Zen and the art of insulin maintenance
David N Bernstein
Commentary: Diabetes Management
-
Zen and the art of insulin maintenance
David N Bernstein
Commentary: Diabetes Management
-
Insulin aspart for the treatment of Type 2 diabetes
V Seshiah, Sanjay Kalra, Vijayam Balaji & Madhuri Balaji
Review Article: Diabetes Management
-
Insulin aspart for the treatment of Type 2 diabetes
V Seshiah, Sanjay Kalra, Vijayam Balaji & Madhuri Balaji
Review Article: Diabetes Management
-
Canagliflozin for Type 2 diabetes: an up-to-date evidence summary
Aris Liakos, Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas
Review Article: Diabetes Management
-
Canagliflozin for Type 2 diabetes: an up-to-date evidence summary
Aris Liakos, Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas
Review Article: Diabetes Management
-
Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?
Torsten Lauritzen, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy EHM Rutten, Annelli Sandbak, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham & Simon J Griffin
Management Perspectives: Diabetes Management
-
Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?
Torsten Lauritzen, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy EHM Rutten, Annelli Sandbak, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham & Simon J Griffin
Management Perspectives: Diabetes Management
-
Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes
Bo Ahren
Review Article: Diabetes Management
-
Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes
Bo Ahren
Review Article: Diabetes Management
Relevant Topics in Clinical